Abstract
<p class="Abstract">This study was conducted to observe the effect of vitamin B<sub>12</sub> supplementation on glycemic control in poorly controlled hyperhomocysteinemic type 2 diabetic patients by measuring HbA1c levels at baseline and 4 weeks. Patient having serum homocysteine more than 15 µmol/L or vitamin B<sub>12</sub> less than 223 pg/mL were enrolled in this study. One group received methylcobalamin 500 µg daily with their usual anti-diabetic therapy and the other group received only suitable anti-diabetic drug therapy. Methylcobalamin 500 µg was given daily for period of 4 weeks. Glycemic control was measured by levels of HbA1c, blood sugar at baseline and at 4 weeks. Serum homocysteine levels was reduced from 21.5 ± 2.6 to 15.4 ± 6.4 (p=0.04) with vitamin B<sub>12</sub> supplementation at 4 weeks. At 4 weeks, HbA1c decreased from 9.9 ± 0.9 to 8.7 ± 0.5 (p&lt;0.01) in vitamin B<sub>12</sub> deficient patients after vitamin B<sub>12</sub> supplementation. There is role of vitamin B<sub>12</sub> in glycemic control in poorly controlled type 2 diabetic patients.</p><p> </p>
Highlights
Hyperhomocysteinemia is observed in type 2 diabetes and it is associated with macroangiopathy, nephropathy and microalbuminuria (Buysschaert et al, 2000; Jager et al, 2001)
Homocysteine is independently associated with the prevalence of diabetic neuropathy in type 2 diabetic patients (Ambrosch 2001)
Vitamin B12 100 μg alternate day with low fat vegan diet resulted in improvement in glycemic and lipid control (Barnard et al, 2006) Therapy with folic acid, vitamin B12, and vitamin B6 significantly decreases the incidence of major adverse events after percutaneous coronary intervention (Schnyder 2002)
Summary
Hyperhomocysteinemia is observed in type 2 diabetes and it is associated with macroangiopathy, nephropathy and microalbuminuria (Buysschaert et al, 2000; Jager et al, 2001). Raised plasma homocysteine was obtained with associated decreased folic acid and vitamin B12 levels in type 2 diabetes subjects (Soinio 2004; Klee 2000; Ebesunun and Obajobi, 2012). Raised homocysteine levels are associated with raised levels of bad cholesterol and decreased levels of good cholesterol (Mahendran et al, 2013; Ramachandran et al, 2012). Homocysteine is independently associated with the prevalence of diabetic neuropathy in type 2 diabetic patients (Ambrosch 2001). There is no evidence that pathological levels of the biochemical markers of B12 are more common in metformin-treated compared with non– metformin-treated patients, despite lowering B12 in serum or plasma (Obeid, 2014)
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call